JAN 2 0 700%

Sheet

PTO/SB/08A (06-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

1

(use as many sheets as necessary)

of

Complete II Known				
Application Number	10/646,391			
Filing Date	8/21/2003			
First Named Inventor	Gleave et al.			
Art Unit	1614 1035			
Examiner Name	Aburan			
Attorney Docket Number	UBC.P-035			

U.S. PATENT DOCUMENTS							
	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant		
Initials*	No.1	Number-Kind Code <sup>2 (*******</sup>		,	Figures Appear		
W12		US- <del>US</del> 6,172,216 B1	1/9/2001	Bennett et al.			
		US-					
		US-					
		US					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-			•		
		US-					
		US-			-		
		US-					
		US-					
		US-					
		US-					
		HS-					

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>a</sup> -Number*- Kind Code <sup>a</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentes or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	Τ¢	
		WO 00/49937 WO 02/22635 A1 WO 03/062421 A1 WO 03/072591 A1	8/31/2000 3/21/2002 7/31/2003 9/4/2003	The University of British Columbia ISIS Pharmaceuticals, Inc. The University of British Columbia The University of British Columbia	<b>дрреаг</b>		

Examiner Signature	() \	4 Bonna	Date Considered	3/22/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of US PTO Patent Documents at <a href="https://www.upsto.gov">www.upsto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction

Substitute for the 449B/RT Complete if Known **Application Number** 10/646,391 INFORMATION DISCLOSURE Filing Date 8/21/2003 First Named Inventor STATEMENT BY APPLICANT Gleave et al. Art Unit TEFE \ 10 (use as many sheets as necessary) Examiner Name Sheet **Attorney Docket Number** UBC.P-035

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Outs		GLEAVE ET AL., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, investigational New Drugs, 2002, Page(s) 145-158, Volume 20	
alb		GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, . Clusterin/Testosterone-Repressed Prostate Message 2, To Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, Page(s) 39-49, Volume 58, XP-002262320	
arb		GLEAVE ET AL., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, 2002, Page(s) 79-92, Volume 21	
am	)	GLEAVE ET AL., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, Page(s) 209-221, Volume 4, XP-009021409	
OUB		JONES ET AL., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, Page(s) 427-431, Volume 34	
Outro		MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo, Clinical Cancer Research, 2000, Page(s) 1655-1663, Volume 6, XP-000960694	
OHB		MIYAKE ET AL., Testosterone-repressed Prostate Message-2 is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer, Cancer Research, 2000, Page(s) 170-176, Volume 60, XP-002907064	
ars		MIYAKE ET AL., Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model, Clinical Cancer Research, 2001, Page(s) 4245-4252, Volume 7, XP-002263075	
OAR		MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, International Journal of Urology, 2001, Page(s) 337-349, Volume 8, XP-002262321	
arb		SENSIBAR ET AL., Prevention of Cell Death Induced by Tumor Necrosis Factor a in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin), Cancer Research, 1995, Page(s) 2431-2437, Volume 55, XP-002930082	
aths		ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, Page(s) 633-645, Volume 27, No. 7, XP-001002844	

Examiner Signature	a tomban	Date Considered	3/1	2/15

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it

displays a va	lid CMB RASS of number.				
Substitute	e for form 1449B/PTO				
	ORMATION DIS	-			
					Complete if Known
	(use as many sheets as	necess	sary)	Application Number	10/646,391
				Filing Date	8/21/2003
				First Named Inventor	Gleave et al.
				Art Unit	1614 1035
				Examiner Name	1 hours
Sheet	3	of	3	Attorney Docket Number	UBC.P-035

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
aths	•	WILSON ET AL., Clusterin is a secreted mammalian chaperone, TIBS, 2000, Pages 95-97, Volume 25	
OHB		WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, Eur. J. Biochem, 1994, Pages 917-925, Volume 91, XP-001146404	
aths		ZANGEMEISTER-WITTKE ET AL., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells, Clinical Cancer Research, 2000, Pages 2547-2555, Volumbe 6, XP-002241562	
OHB		ZELLWEGER ET AL., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of 2'O'(2-Methoxy)Ethyl Chemistry, The Journal of Pharmacology and Experimental Therapeutics, 2001, Pages 934-940, Volume 298, No. 3, XP-002262318	
alth		ZELLWEGER ET AL., Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin, Neoplasia, 2001, Pages 360-367, XP-009004604	

Examiner	(, \sqrt{1})	V-00 - 11 11 .	Date	1 (2) 182-
	11 11			1 3177 185
Signature		1000	Considered	1 11000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments